Illumina (NASDAQ:ILMN) Director Sells $56,543,325.09 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 283,269 shares of Illumina stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $199.61, for a total value of $56,543,325.09. Following the transaction, the director owned 2,089,425 shares in the company, valued at $417,070,124.25. This trade represents a 11.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Illumina Stock Performance

ILMN traded down $6.15 during midday trading on Thursday, reaching $193.72. The company had a trading volume of 4,268,800 shares, compared to its average volume of 1,934,392. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average of $179.92 and a two-hundred day moving average of $148.41. The company has a market cap of $29.25 billion, a P/E ratio of 36.14, a P/E/G ratio of 2.86 and a beta of 1.45. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $207.00.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the firm earned $1.19 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

A number of hedge funds have recently bought and sold shares of the business. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter worth $25,000. Creative Capital Management Investments LLC raised its holdings in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new stake in shares of Illumina during the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC purchased a new position in Illumina during the 4th quarter valued at $26,000. Finally, Activest Wealth Management grew its position in Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent analyst reports. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Canaccord Genuity Group boosted their target price on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a report on Monday. Barclays upped their target price on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Illumina currently has an average rating of “Hold” and an average price target of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.